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Abstract
Background: Depression is a serious mental health problem and is common in children and adolescents. Online
interventions are promising in overcoming the widespread undertreatment of depression and in improving the
help-seeking behavior in children and adolescents.
Methods: The multicentre, randomized controlled E.motion trial is part of the German ProHEAD consortium (Promoting
Help-seeking using E-technology for ADolescents). The objective of the trial is to investigate the efficacy and
cost-effectiveness of two online interventions to reduce depressive symptomatology in high-risk children and
adolescents with subsyndromal symptoms of depression in comparison to an active control group. Participants will be
randomized to one of three conditions: (1) Intervention 1, a clinician-guided self-management program (iFightDepression®);
(2) Intervention 2, a clinician-guided group chat intervention; and (3) Control intervention, a psycho-educational website on
depressive symptoms. Interventions last six weeks. In total, N= 363 children and adolescents aged ≥ 12 years with Patient
Health Questionnaire-9 modified for Adolescents (PHQ-A) scores in the range of 5–9 will be recruited at five study sites
across Germany. Online questionnaires will be administered before onset of the intervention, at the end of the intervention,
and at the six-month follow-up. Further, children and adolescents will participate in the baseline screening and the one- and
two-year school-based follow-up assessments integrated in the ProHEAD consortium. The primary endpoint is depression
symptomatology at the end of intervention as measured by the PHQ-A score. Secondary outcomes include depression
symptomatology at all follow-ups, help-seeking attitudes, and actual face-to-face help-seeking, adherence to and satisfaction
with the interventions, depression stigma, and utilization and cost of interventions.
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Discussion: This study represents the first randomized controlled trial (RCT) investigating efficacy and cost-effectiveness of
two online interventions in children and adolescents aged ≥ 12 years at risk for depression. It aims to provide a better
understanding of the help-seeking behavior of children and adolescents, potential benefits of E-mental health interventions
for this age group, and new insights into so far understudied aspects of E-mental health programs, such as potential
negative effects of online interventions. This knowledge will be used to tailor and improve future help offers and programs
for children and adolescents and ways of treatment allocation.
Trial registration: German Register for Clinical Trials (DRKS), DRKS00014668. Registered on 4 May 2018.
International trial registration took place through the “international clinical trials registry platform” with the
secondary ID S-086/2018.
Keywords: Depression, Depressive symptoms, Children, Adolescents, Adolescence, Prevention, Internet-based,
Psychological intervention, Self-management, ProHEAD
Background
Depressive disorders are severe mental illnesses with
overall prevalence rates, measured from point prevalence
up to 12-month prevalence, in the range of 2.6–19.4%
among children and adolescents (C&A) [1–7]. Rates rise
in adolescence compared to childhood [8] and show a
stronger female preponderance in adolescents [2, 6]. De-
pression in C&A has a marked negative impact regard-
ing poor academic performance and social dysfunction
and predicts adverse mental health outcomes such as re-
currence of depressive symptoms, substance abuse,
self-harm, suicidal ideation, and attempted and com-
pleted suicide [9–11]. Due to the high burden of depres-
sion for both personal and societal areas, early
intervention and prevention of its onset are of utmost
importance [12, 13]. Targeting subthreshold depression
in particular is of enormous potential as subthreshold
depression in adolescents is a substantial risk factor for
the onset of major depression [14]. However, currently
the vast majority of C&A with subthreshold depressive
symptoms does not seek professional help and does not
receive professional support. Barriers to help-seeking in-
clude poor mental health literacy, shame and
stigmatization related to depression [15], but also symp-
toms of depression itself, such as feelings of worthless-
ness or guilt. Internet-based interventions present a
promising approach to overcome these barriers, espe-
cially as various studies have shown that a high percent-
age of C&A use the Internet for health-related purposes
(e. g. seeking health-related information and support
communities; [16]). Internet-based interventions provide
low-threshold access to evidence-based information,
self-help tools, peer support, and professional counseling
and could thus help in reaching target populations who
might otherwise not seek treatment.
The development of online-delivered interventions and
the use of smartphone systems and apps for monitoring
and treatment of depression has increased enormously
during recent years [17]. Therapist-delivered online
cognitive behavioral therapy (CBT) for depression has
been shown to be both effective and cost-effective [18]. In
addition, various guided and unguided Internet-based in-
terventions for adults with depression have been devel-
oped and their efficacy has been shown [12]. Specifically,
self-management and self-help reduce the burden of
sub-threshold and full-syndrome forms of depression in
adults [19]. Comparisons of Internet-based interventions
for depression with face-to-face treatment did not indicate
differences in efficacy between the different treatment for-
mats [20].
Despite the clear benefits of Internet-based interven-
tions for depression in adults, there is a lack of studies
specifically focusing on C&A [21, 22]. Several pilot trials
have been published recently, providing preliminary re-
sults for the effectiveness of Internet-based interventions
for the treatment of depression in C&A. These include,
among others, an Internet-based intervention for at-risk
of suicide school students, which has resulted in reduced
suicidal ideation, hopelessness, and depressive symptoms
[23], a randomized controlled trial (RCT) on a spiritual-
ity informed e-mental health tool as an intervention for
major depressive disorder in adolescents and young
adults [24], and a RCT on a school-based CBT program,
which resulted in significant decreases in depression
symptomatology and suicidality [25]. Another self-di-
rected Internet-based intervention for depression was
delivered as part of the high school curriculum and re-
sulted in a reduction of depressive symptoms in adoles-
cent girls [26].
While most programs include online information, exer-
cises, and questionnaires accessible to the participants, chat
treatments for C&A at risk for depression have not been
studied well so far. Two randomized trials in adolescents
and young people with depressive symptoms investigating
the effectiveness of an Internet-based, solution-focused,
brief chat treatment and an Internet-based chat treatment
based on principles of CBT, respectively, showed positive
effects of the respective treatment regarding a reduction of
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depressive symptoms in comparison to a wait-list control
condition [22, 27].
In summary, there is preliminary evidence for the ef-
fectiveness of Internet-based interventions in C&A at
risk for depression. However, most of the identified trials
had either limited results, only short-term follow-up pe-
riods (often due to waitlist control conditions), or were
self-guided. Studies with longer-term follow-up and
guidance are currently lacking [22]. To address the gaps
identified in the literature, the E.motion trial will be con-
ducted to investigate the efficacy and cost-effectiveness
of two different online interventions to reduce depres-
sive symptomatology in high-risk C&A aged ≥ 12 years
with subsyndromal symptoms of depression.
Methods/Design
Design
The E.motion trial is a multicentre, three-arm RCT com-
paring two online interventions with an active control
group. Participants will be randomized to one of three
conditions, each with a duration of six weeks: (1) Inter-
vention 1, a clinician-guided self-management program
(iFightDepression®); (2) Intervention 2, a clinician-guided
group chat intervention; and (3) Control intervention, a
psycho-educational website on depressive symptoms.
Recruitment and study procedures
This trial is part of the ProHEAD consortium (Promot-
ing Help-seeking using E-technology for ADolescents)
aiming to assess new access pathways for prevalent men-
tal health problems in C&A. Within the ProHEAD con-
sortium, C&A with mental health problems and/or high
risk for mental health problems will be allocated to one
of five RCTs [28–31]. A large-scale school-based sample
of N = 15,000 C&A aged ≥ 12 years attending school
grades 6–13 will be recruited within the ProHEAD con-
sortium in five urban areas geographically distributed
across Germany (Hamburg, Heidelberg, Leipzig, Mar-
burg, Schwäbisch Gmünd). The ProHEAD consortium
includes online assessments of mental health problems
and health-risk behaviors (i.e. general mental health
problems, eating disorder symptoms, alcohol use, and
depressive symptoms) at baseline and at two annual
follow-ups. All assessments within the ProHEAD con-
sortium will be administered through on-site visits in
the school classes and C&A will complete the question-
naires in the respective school’s local computer rooms
(for further details on study procedures within the Pro-
HEAD consortium, see study protocol by Kaess et al.,
published in this special issue).
Written informed consent will be obtained from all
participating C&A and their legal guardians before ad-
ministering baseline screening assessments. Participants
will be informed that after completing the baseline
screening, they will receive an invitation to participate in
one out of five fully remote Internet-based intervention
trials (group 1, general mental health problems; group 2,
eating disorder symptoms; group 3, at-risk alcohol use;
group 4, depressive symptoms, E.motion trial; group 5,
no mental health problems, prevention trial). Within
each of these RCTs, different intervention and preven-
tion programs, respectively, will be compared and the al-
location to a specific RCT will be based on meeting
pre-defined cut-off scores in the baseline screening.
Participants for the E.motion trial will be recruited from
the ProHEAD consortium. Following the baseline screening
within the ProHEAD consortium, an estimated number of
N= 1500 C&A reporting subthreshold depressive symptoms
and meeting eligibility criteria for the E.motion trial will be
invited to participate in the trial. In the case of participation,
these C&A will be randomized to one of the three treatment
arms, as illustrated in Fig. 1. Participants not meeting eligibil-
ity criteria will be included in one of the other four RCTs
within the ProHEAD consortium (see information on eligi-
bility criteria below). A schedule of enrolment, interventions,
and assessments is included in Fig. 2 and a Standard Proto-
col Items: Recommendations for Intervention Trials
(SPIRIT) Checklist is provided in Additional file 1.
Eligibility criteria
All eligibility criteria will be assessed through the base-
line screening of the ProHEAD consortium. C&A aged
≥ 12 years and reporting current subthreshold depressive
symptoms will be included in the trial. Subthreshold de-
pressive symptoms will be operationalized with the Pa-
tient Health Questionnaire-9 modified for Adolescents
(PHQ-A) [32, 33], with scores in the range of 5–9. Inclu-
sion criteria further comprise sufficient German
language skills and Internet access. There are no restric-
tions for participants for engaging in additional (depres-
sion-related) interventions or treatments.
Participants reporting either other mental health prob-
lems (general mental health problems, eating disorder
symptoms, or alcohol misuse) or no clinically relevant
levels of psychopathology will be allocated based on their
specific symptom profiles to one of the other four RCTs
within the ProHEAD consortium. Other current mental
health problems will be operationalized as scores above
the clinical cut-off in one or more of the following ques-
tionnaires: Strengths and Difficulties Questionnaire (SDQ)
[34]; Short Evaluation of Eating Disorders (SEED) [35];
Weight Concerns Scale (WCS) [36]; Car, Relax, Alone,
Forget, Friends, Trouble (CRAFFT-d) [37]; and Alcohol
Use Disorders Identification Test (AUDIT) [38]. Partici-
pants meeting inclusion criteria for more than one RCT
will be randomly allocated to one of the RCTs for which
they are eligible.
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Assessments
All interventions will have a duration of six weeks for the
individual participant. Assessments specific to the E.mo-
tion trial will be conducted before the onset of the inter-
vention period, at the end of the intervention (six weeks
after start of intervention), and at the six-month
follow-up. Further, C&A will participate in the baseline
screening and the regular one- and two-year school-based
follow-up assessments integrated in the ProHEAD
consortium, to track long-term outcome of the interven-
tions (see Fig. 2). All assessments will consist of
self-administered questionnaires and will be carried out
online using secure links sent via automated e-mails.
Randomization
Following the school-based baseline screening within the
ProHEAD consortium, participants eligible for the E.mo-
tion trial will receive an e-mail including information
Fig. 1 Trial flow diagram. Assessments within the E.motion trial will be conducted at baseline, at the end of intervention (six weeks after onset of
intervention), and at six-month follow-up. Further, participants will complete the school-based baseline screening and one- and two-year school-based
follow-up assessments integrated in the ProHEAD consortium. * For further details on other RCTs within the ProHEAD consortium, see other study
protocols published in this special issue. PHQ-A Patient Health Questionnaire-9 modified for Adolescents
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about the trial and access details for the baseline assess-
ment within the E.motion trial. After completing this as-
sessment, participants will be randomized with equal
probability (in a 1:1:1 ratio) to one of the three interven-
tion groups. The assignment to the three conditions will
be randomized, stratified for gender and school type.
Randomization will be conducted externally and follow a
permutated block design. Following randomization, par-
ticipants will be contacted again via e-mail to be in-
formed about their allocation to the respective
intervention group and receive access details for the spe-
cific online programs. Blinding is not possible as the
study assistants will be involved in delivering the inter-
ventions. However, the risk of a potential bias is
considered minimal as the study outcome variables are
exclusively based on self-report. For all treatment arms,
the intervention will be discontinued at any time for par-
ticipants who withdraw consent to participate in the
trial.
Interventions
Intervention 1: iFightDepression® (iFD®) tool
The first intervention group will complete the iFightDe-
pression® (iFD®) tool, which is an online, clinician-guided,
self-management program that aims to help individuals
with mild to moderate depression to self-manage their
symptoms (tool accessible at https://tool.ifightdepression.-
com) [39]. The tool consists of six core modules related to
Fig. 2 Schedule of enrolment, interventions, and assessments. * Assessments within the E.motion trial will be conducted at the end of intervention
(six weeks after onset of intervention) and at six-month follow-up. Further, participants will complete the one- and two-year school-based follow-up
assessments integrated in the ProHEAD consortium. PHQ-A Patient Health Questionnaire-9 modified for Adolescents, IASMHS Inventory of Attitudes
Toward Seeking Mental Health Services, GHSQ General Help-Seeking Questionnaire, AHSQ Actual Help-Seeking Questionnaire, DSS Depression Stigma
Scale, MRV Mannheimer Modul zum Ressourcenverbrauch, KIDSCREEN-10 Health-related quality of life measure for children and adolescents, ZUF-8
German version of the Client Satisfaction Questionnaire, INEP Inventory for the Assessment of Negative Effects of Psychotherapy
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behavioral activation, sleep and mood monitoring, and
cognitive restructuring (“Thinking, feeling and doing,”
“Planning and doing things that you enjoy,” “Getting
things done,” “Recognizing negative thoughts,” “Changing
negative thoughts,” and “Sleep and depression”) and three
optional modules related to psychosocial issues and
healthy lifestyle habits (“Healthy lifestyle,” “Relationships,”
and “Social anxiety”). Each module comprises written in-
formation, worksheets (online or printable), exercises, and
a voluntary mood rating using the PHQ-A with a graph-
ical output display. In addition, emergency contact mater-
ial is provided. Participants will be asked to use the tool
for six weeks on a regular basis and complete one work-
shop per week. The self-management program has a total
duration of six weeks and participants will be guided by a
trained clinical psychologist giving administrative and mo-
tivational support and exploring how well participants
were able to integrate the exercises into their daily
routine.
Two versions of the iFD® tool (one for adults and one
for young people) were developed within the EU-funded
project PREDI-NU [39]. Previous research confirmed
the feasibility of the tool [39, 40]. Oehler C, Görges F,
Böttger D, Hug J, Koburger N, Kohls E, et al: Efficacy of
an internet-based self-management intervention for
adult primary care patients with mild and moderate de-
pression or dysthymia – a study protocol, submitted.
Within the E.motion trial, the tailored version of the tool
for young people, incorporating less formal language
and additional age-appropriate modules on relationships
and social anxiety, will be used. iFD® was developed
based on existing evidence, best practice recommenda-
tions, and user and expert consensus. The tool is free to
use and is intended to help individuals self-manage their
symptoms of depression and to promote recovery. It is
based on principles of CBT, which has been proven to
be effective in treating depression [41, 42]. Associated
worksheets and exercises encourage users of the tool to
practice and consolidate new skills and to promote
self-monitoring. The tool is currently available in 11
languages.
Intervention 2: Group chat
The second intervention group will receive a
clinician-guided, online, group chat intervention based
on a cognitive-behavioral approach. The intervention
will address the following core elements: (1) information
about depressive symptoms; (2) diagnosis of depression
and etiological factors; (3) treatment options: psycho-
therapy; (4) treatment options: medication; (5) social
support and dealing with stigmatization in the context
of depression; and (6) emergency strategies and help
seeking. The intervention will consist of six 90-min
group chat sessions, which will be held once per week.
Sessions will be scheduled at fixed times and a secured
chat room will be specifically arranged for the sessions.
The group size will be 6–10 participants, depending on
recruitment and attrition rates. Groups will be “open,”
i.e. participants can join at any time during the interven-
tion period. Participants will communicate via written
messages, allowing a synchronous communication in
real time. Participation in the chat will be under
self-chosen pseudonyms to ensure confidentiality.
The chats will be moderated by a trained clinical
psychologist and the intervention will be manualized to
maximize treatment adherence. The psychologists deliv-
ering the intervention are experienced in individual and
group treatment of persons with depression and depres-
sive symptoms, being aware of the medical consequences
of depressive symptoms, potential suicidal ideation, and
self-harm. These aspects will be assessed regularly dur-
ing chat sessions. Each chat session will be focused on
one of the six core elements as mentioned above,
whereas the specific chat agenda will be set at the begin-
ning of each session and will be based on the current
questions and needs of each participant. Sessions will be
used to provide information on different aspects of de-
pression and to discuss and answer questions within the
group. A specific focus will be given to positive commu-
nication among participants and to the peer-to-peer ex-
change, which has been shown to be of additional help
in patients with depression and other mental disorders
[43–47]. Kohls E, Hug J, Stahl M, Driessen P, Roemer C,
Wollschlaeger E, et al: Peer counselling in depression
care: a pilot study in an inpatient setting, submitted.
Chat protocols will be stored for supervision purposes.
Control intervention
Trial participants in the control intervention group will
have access to structured online psycho-educational
modules on depression (e.g. symptoms, diagnosis, treat-
ment, medication, psychotherapy, other forms of treat-
ment like self-help) for a duration of six weeks. There
will be no therapeutic guidance or support. The partici-
pants in the control condition will be offered to inform
themselves about the different aspects of depression by
reading the different psycho-educational modules on
their own schedule, e.g. one module per week.
Intervention fidelity
The guiding therapists for the iFD® tool will be clinical
psychologists who have qualified through completing a
guidance webinar and a short test before gaining access
to the tool. For the group chat, clinical psychologists will
conduct the chats and will have completed a training ac-
cording to the group chat intervention manual before
the start of the intervention. For both interventions 1
and 2, regular supervision will be conducted by a senior
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psychiatrist (CRK) specializing in depression, who has
been part of the project team developing the iFD® tool
and has developed the manual for the clinician-guided
group chat intervention.
Outcomes and measures
Primary outcome
The primary outcome of the trial is depression symp-
tomatology at the end of intervention as measured by
the PHQ-A score. The depression module of the
PHQ-A [32, 33] comprises nine items assessing depres-
sive symptoms based on the diagnostic criteria for de-
pression according to the fourth edition of the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) [48]. Respondents rate the frequency of the
symptoms over the previous two weeks on a four-point
Likert scale (0 = “not at all” to 3 = “nearly every day”). A
sum score will be computed with higher scores indicating
higher levels of depressive symptomatology. The PHQ-9
for adults has shown good reliability, validity, and sensitiv-
ity to change [49, 50].
Secondary outcomes
Secondary outcomes will be assessed at baseline, at the
end of intervention, and at six months, one year, and
two years after the start of the intervention by using the
following measures: the PHQ-A [32, 33] will be used to
assess depression symptomatology. Help-seeking atti-
tudes will be assessed by the Inventory of Attitudes To-
ward Seeking Mental Health Services (IASMHS) [51]
and actual face-to-face help-seeking will be measured
with the General Help-Seeking Questionnaire (GHSQ)
[52] and the Actual Help-Seeking Questionnaire (AHSQ)
[53]. Adherence to the interventions (iFightDepression®
and group chat) will be measured with participation
rates and satisfaction with the interventions as well as
possible negative effects will be assessed by the German
version of the Client Satisfaction Questionnaire (ZUF-8)
[54] and the Inventory for the Assessment of Negative
Effects of Psychotherapy (INEP) [55], respectively. The
Depression Stigma Scale (DSS) [56] will be used to as-
sess the stigma associated with depression.
Finally, cost-effectiveness and cost-utility analyses will
be conducted. Data on the cost of interventions will be
compared to study outcomes to determine the incre-
mental cost-effectiveness ratio (ICER) of interventions.
The ICER is defined as the differential cost of a new
treatment and treatment as usual, divided by the out-
come differential of the two. Cost-utility analyses will
provide information on cost per quality-adjusted life
years (QALYs). QALYs are measures combining the add-
itional life years gained by a certain healthcare interven-
tion or program with the quality of life a subject
attributes to this lifespan into one single parameter.
Thus, QALYs are subjective and universally applicable
outcome parameters for comparing health benefits
across sectors, disorders, samples, or populations. It can
be assessed in both patients and healthy individuals.
Health-related quality of life will be assessed using the
KIDSCREEN-10 [57, 58]. In addition, the health service
utilization of the participants will be assessed by the
“Mannheimer Modul Ressourcenverbrauch” (MRV) [59]
and transformed into cost estimates. For this purpose, a
catalog of so-called “unit costs” will be compiled for all
types of treatments, services, or other healthcare mea-
sures that were used.
Sample size calculation
We assume a small to medium effect (superiority of the
two intervention groups over the control condition) on
depressive symptomatology at postline after treatment as
reported in meta-analyses on interventions for the pre-
vention of depression in C&A [60]. Non-inferiority of
the two active intervention groups is assumed. Repeated
measures mixed models will be conducted (time*group
interaction, alpha = 5%). Assuming a small to medium
effect of f = 0.13, a lost-to-follow-up rate of 20%, and
correlations of 0.2 among repeated measures, n = 363 in-
dividuals (n = 121 per group) need to be recruited for a
test of the global hypothesis with 90% power. In case the
ANOVA shows significant differences, post-hoc pairwise
group comparisons can be conducted at a power of
about 80% (Bonferroni correction) with the planned
sample size.
Participants will be recruited within the ProHEAD
consortium from the school-based sample of N = 15,000
screened C&A. Based on prevalence rates of approxi-
mately 5–12% of subthreshold depression in adolescents
[14], 10% or n = 1500 of the screened C&A are expected
to be eligible for inclusion in the trial. Thus, in order to
meet the required sample size of n = 363, about 25% of
eligible C&A would have to be willing to participate in
the trial.
Criteria for the allocation of participants to the five in-
dividual ProHEAD trials are based on latest scientific
evidence. However, this is the first time that the overall
algorithm is applied on a consortium-wide basis simul-
taneously screening for various mental health problems.
Therefore, an intermediate data analysis will be con-
ducted following completion of 10% of the screening as-
sessments (N = 1500) in order to determine the actual
allocation ratio to the five ProHEAD trials and to adjust
the screening algorithm if necessary.
Statistical analysis plan
All analyses will be conducted in accordance with
intention-to-treat (ITT) principles, i.e. all randomized
Baldofski et al. Trials           (2019) 20:53 Page 7 of 11
individuals will be included in the analysis [61]. In
addition to the primary ITT analysis, per-protocol ana-
lysis will be conducted.
For the primary outcome, repeated measures mixed
models (time*group interaction) will be conducted to
test for differences in efficacy between the intervention
groups. In case of statistically significant results, group
differences will be investigated using post-hoc pairwise
comparisons (Bonferroni correction). Secondary analyses
using repeated measures mixed models will be per-
formed on variables related to help-seeking behavior and
depression stigma. In addition, repeated measures mixed
models will be conducted to examine long-term group
differences in PHQ-A scores at the six-month, one-year,
and two-year follow-up timepoints, respectively. All ana-
lyses will include testing for interaction effects with
study site (time*group*study site interaction).
Additionally, cost-effectiveness analyses and cost-utility
analyses will be conducted. Cost-effectiveness analyses in-
clude the calculation of the ICER. The ICER indicates the
additional cost for each additional (primary) outcome that
has to be paid under routine care conditions. During these
analyses, standard health economy techniques will be ap-
plied, such as bootstrapping techniques for estimating ICER
variability, the calculation of cost-effectiveness acceptability
curves (CEAC), and calculation of willingness-to-pay (WTP)
criteria [62, 63]. In addition, a cost-utility study will be con-
ducted that requires the transformation of longitudinal qual-
ity of life data (assessed with the KIDSCREEN-10) into
preference measures, for the calculation of QALYs lost or
gained during follow-up in order to calculate costs per
QALY of the intervention.
Analyses will be performed using IBM SPSS Statistics
and p values < 0.05 will be considered statistically
significant.
Organization, quality assurance, and data management
Research data will be collected in a pseudonymized
manner by means of online questionnaires. Data quality
will be ensured by conducting automatic validity and
range checks at data entry. The confidentiality of partici-
pants is secured by providing unique study identifiers
unrelated to the real name. All study-related data will be
stored on secure servers at the principal investigator’s
institution with frequent back-up procedures in place.
Data will be stored for 10 years at the primary research
institution. Data handling and access will follow German
and European Union legal regulations concerning data
protection and data security. The Coordination Center
for Clinical Trials (KKS) Heidelberg will monitor
study-related procedures at the five recruiting centers.
Specifically, the recruitment of schools within the target
regions and the recruitment of students within these
schools will be monitored in order to ensure adherence
to the study manual and documentation guidelines as
well as equivalent procedures at all sites. In addition, an
independent Data and Safety Monitoring Board (DSMB)
as defined in ICH-GCP will assess the progress of the
trial, data safety, and the clinical efficacy endpoints.
Safety reporting
There is no obvious risk for participating C&A. The study
does not involve any restriction to standard care. All par-
ticipants will receive information on where to seek help
for mental health problems within the ProHEAD consor-
tium. In case of C&A reporting suicidal plans or suicide
attempts, special emergency procedures will be put in
place allowing immediate contact of the participant in
order to assess risks and refer to appropriate care. Poten-
tial serious adverse events (SAE) will be reported to the
local ethics committee, the DSMB, and the KKS.
Dissemination
Trial results will be published in peer-reviewed inter-
national journals and will be presented at national and
international conferences. Substantial protocol modifica-
tions will be communicated to the ethics committee,
trial registry, DSMB, and all relevant parties.
Discussion
This study represents the first RCT investigating efficacy
and cost-effectiveness of two online interventions for
C&A at risk for depression. To our knowledge, this is the
first study, aiming at large scale, sustainable implementa-
tion of Internet-based indicated prevention of depression
within an integrated infrastructure that aims at health pro-
motion, prevention of clinical symptoms, and facilitating
help-seeking. Research on the cost-effectiveness of such
interventions is sparse as well and the results of the study
will provide a strong basis for decision-making for stake-
holders and policy makers in the field. Also, the trial will
provide new insights into so far understudied aspects of
E-mental health programs, such as potential negative ef-
fects of online interventions and user characteristics. Fur-
ther, this RCT will overcome current shortcomings of
available studies, with a particular focus on professional
guidance by mental health professionals for participants
and longer follow-up periods and provide an internation-
ally consented, guided self-management tool which has
been broadly used in adults with milder forms of depres-
sion in 11 different languages/countries already.
This RCT will advance the state of the art by bringing
an established, guided, online-delivered self-management
approach, which is well implemented into routine care,
to the large population of unrecognized C&A with sub-
threshold depression being at risk of developing a de-
pressive disorder.
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In summary, the trial will: (1) significantly add to the
existing evidence on Internet-based indicated prevention
of depression in C&A at risk for the development of de-
pression; (2) be the first study to investigate effects of
Internet-based indicated prevention on help-seeking in
C&A with subthreshold depressive symptoms; and (3)
provide cost-effectiveness data on Internet-based indi-
cated depression prevention.
Trial status
The trial was registered at the German Register for Clin-
ical Trials (DRKS) under the title “ProHEAD – Promot-
ing Help-seeking using E-technology for Adolescents.
Sub-project 4: Efficacy and cost-effectiveness of two on-
line interventions for children and adolescents at risk for
depression (E.motion trial)”, identification code:
DRKS00014668. International trial-registration took
place through the “international clinical trials registry
platform” with the secondary ID S-086/2018.
The recruitment period for the trial will start in Octo-
ber 2018 and is predicted to continue until March 2020.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) Checklist. (DOC 123 kb)
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